Clinical Trials Logo

Non-Hodgkin Lymphoma clinical trials

View clinical trials related to Non-Hodgkin Lymphoma.

Filter by:

NCT ID: NCT03615105 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Start date: July 25, 2018
Phase: Phase 2
Study type: Interventional

This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.

NCT ID: NCT03436771 Terminated - Multiple Myeloma Clinical Trials

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Start date: February 19, 2018
Phase:
Study type: Observational

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

NCT ID: NCT03422679 Terminated - Breast Cancer Clinical Trials

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Start date: December 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

NCT ID: NCT03379051 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Start date: March 27, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

NCT ID: NCT03311126 Terminated - Clinical trials for Mantle Cell Lymphoma

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Start date: October 19, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects who have not received prior cytotoxic chemotherapy for their MCL (i.e., prior single agent rituximab is permitted, prior involved-field radiotherapy is permitted).

NCT ID: NCT03272633 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Start date: October 26, 2020
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

NCT ID: NCT03207256 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Start date: August 9, 2017
Phase: Phase 2
Study type: Interventional

This is an open label compassionate use trial of Ublituximab and TGR-1202 in combination or as single agents in patients currently receiving treatment on Ublituximab and/or TGR-1202 trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.

NCT ID: NCT03132584 Terminated - Clinical trials for Diffuse Large B Cell Lymphoma

Cyclophosphamide and Alemtuzumab In Lymphoma

Start date: July 30, 2017
Phase: Phase 1
Study type: Interventional

This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: - Cyclophosphamide - Alemtuzumab

NCT ID: NCT03065790 Terminated - Clinical trials for Non-Hodgkin Lymphoma

Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

Start date: February 6, 2017
Phase:
Study type: Observational

Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.

NCT ID: NCT02953509 Terminated - Clinical trials for Non Hodgkin Lymphoma

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Start date: November 21, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objectives of this study are: - To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). - To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in autologous stem cell transplant (ASCT) ineligible DLBCL participants.